Patent Assignment
Reel/Frame 049344/0688
Assignment of Assignor's Interest
Recorded: 2019-06-03
Pages: 14
Assignor
REGULUS THERAPEUTICS INC.
Executed: 2019-05-08
Assignee
SANOFI
54 RUE LA BOÉTIE, PARIS, 75008, FRANCE
Covered Properties
(29)
Microrna Compounds and Methods for Modulating Mir-21 Activity
PCT:
PCT/US2013/037913 ↗
Methods for Treatment of Alport Syndrome
PCT:
PCT/US2013/063884 ↗
Methods for Treatment of Alport Syndrome
PCT:
PCT/US2018/031094 ↗
Microrna Compounds and Methods for Modulating Mir-21 Activity
Methods for Treatment of Alport Syndrome
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Methods for Treatment of Alport Syndrome
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Methods for Treatment of Alport Syndrome
Microrna Compounds and Methods for Modulating Mir-21 Activity
Methods for Treatment of Alport Syndrome
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
15/704,749 →
Publication:
US 2018/0155719
Methods for Treatment of Alport Syndrome
Application:
15/948,450 →
Publication:
US 2018/0298385
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application:
15/954,159 →
Publication:
US 2018/0305691
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application:
15/976,060 →
Publication:
US 2018/0355355
Methods for Treatment of Alport Syndrome
Application:
16/352,324 →
MicroRNA Compounds and Methods for Modulating MiR-21 Activity
Application:
61/478,767 →
MicroRNA Compounds and Methods for Modulating MiR-21 Activity
Application:
61/565,779 →
Methods for Treatment of Alport Syndrome
Application:
61/711,514 →
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
61/717,927 →
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
61/741,783 →
Publication:
US 2012/0270928
Methods for Treatment of Alport Syndrome
Application:
61/779,137 →
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
61/779,913 →
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
61/895,583 →
Methods for Treatment of Alport Syndrome
Application:
62/501,699 →
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 23, 2011
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS, INC.
Reel/Frame 026324/0714 →
Assignment of Assignor's Interest
Feb 27, 2012
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS INC.
Reel/Frame 027764/0888 →
Assignment of Assignor's Interest
May 16, 2013
From: BHAT, BALKRISHEN; MARCUSSON, ERIC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 030430/0138 →
Assignment of Assignor's Interest
Dec 20, 2013
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031825/0801 →
Assignment of Assignor's Interest
Jan 2, 2014
From: DUFFIELD, JEREMY; BHAT, BALKRISHEN; MACKENNA, DEIDRE
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031872/0727 →
Assignment of Assignor's Interest
Jul 29, 2014
From: BHAT, BALKRISHEN
To: REGULUS THERAPEUTICS INC.
Reel/Frame 033409/0114 →
Security Interest
Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
Assignment of Assignor's Interest
Sep 12, 2018
From: WRIGHT, TIMOTHY
To: REGULUS THERAPEUTICS INC.
Reel/Frame 046856/0778 →
Release of Security Interest
Nov 7, 2018
From: OXFORD FINANCE LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 047445/0286 →
Release of Security Interest
May 14, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
To: REGULUS THERAPEUTICS INC.
Reel/Frame 067402/0782 →